Y-mAbs Therapeutics Reports Mixed Financial Results with Profitability Improvements and Sales Decline in August 2025

Aug 08 2025 12:00 AM IST
share
Share Via
Y-mAbs Therapeutics, Inc. announced its financial results for the quarter ending June 2025, highlighting improvements in profitability metrics, including net and operating profits. However, net sales declined, and cash reserves decreased, indicating challenges in liquidity and increased reliance on debt for operations.
Y-mAbs Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reported its financial results for the quarter ending June 2025 on August 8, 2025. The company has demonstrated notable trends in its financial metrics, particularly in profitability measures.

Net profit reached its highest level at USD -3.24 million, reflecting a positive trajectory over the last five periods. Similarly, operating profit also peaked at USD -5.55 million, indicating a favorable trend in operational performance. Pre-tax profit followed suit, marking its highest at USD -3.23 million, with significant growth observed compared to previous periods. Earnings per share (EPS) improved to USD -0.07, suggesting enhanced profitability for shareholders.

On the cost side, raw material expenses have decreased by 0.78% year-over-year, which may contribute to an improved profit margin. However, the company faced challenges as net sales fell to USD 19.52 million, down 11.91% from the average of the previous four periods. Additionally, cash and equivalents reached a low of USD 122.6 million, indicating a decline in short-term liquidity. The debt-equity ratio also rose to -67.63%, suggesting increased reliance on borrowing for operational funding.

Overall, Y-mAbs Therapeutics, Inc. has experienced evaluation changes in its financial standing, reflecting both positive developments and areas of concern.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Is Y-mAbs Therapeutics, Inc. overvalued or undervalued?
Sep 20 2025 06:35 PM IST
share
Share Via
Is Y-mAbs Therapeutics, Inc. overvalued or undervalued?
Jun 25 2025 09:13 AM IST
share
Share Via
What does Y-mAbs Therapeutics, Inc. do?
Jun 22 2025 06:56 PM IST
share
Share Via
How big is Y-mAbs Therapeutics, Inc.?
Jun 22 2025 06:10 PM IST
share
Share Via
Most Read
Why is Knowledge Marine falling/rising?
8 seconds ago
share
Share Via
Why is Triumph Intl. falling/rising?
20 seconds ago
share
Share Via
Why is Parvati Sweetner falling/rising?
26 seconds ago
share
Share Via
Why is Bonlon Industrie falling/rising?
27 seconds ago
share
Share Via
Why is FratelliVineyard falling/rising?
33 seconds ago
share
Share Via
Why is V R Films & Stud falling/rising?
54 seconds ago
share
Share Via
Why is Ganga Forging falling/rising?
56 seconds ago
share
Share Via